Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer   The Phase 3 monarchE trial evaluating the effects of two years of Verzenio treatment added to